# Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy

> **NCT01811485** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 171 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** LMF237 50/250 mg
- **DRUG:** LMF237 50/500 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01811485
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2015-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01811485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01811485, "Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01811485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*